Final Survival Analysis Of Nsgo-Avanova2/Engot-Ov24: Combination Of Niraparib And Bevacizumab Versus Niraparib Alone As Treatment Of Recurrent Platinum-Sensitive Ovarian Cancer-A Randomized Controlled Chemotherapy-Free Study.

Mansoor Raza Mirza,Gitte-Betina Nyvang,Bente Lund,Rene dePont Christensen,Theresa Louise Werner,Susanne Malander,Line Bjørge,Michael J. Birrer,Maarit Anttila,Gabriel Lindahl,Sakari Hietanen, Maria Dimoula, Ulla Peen,Kristine Madsen,Anja Knudsen,Synnove Staff,Nicole Buchner Vinum,Maj Kamille Kjeldsen,Elisabeth Avall-Lundqvist,Johanna Unelma Maenpaa

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 7|浏览7

暂无评分

摘要

6012Background: We previously reported significantly improved progression-free survival (PFS) with the chemotherapy-free regimen of niraparib and bevacizumab compared to niraparib alone, in women w...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要